Circulating immune checkpoints predict heart failure outcomes

Circulating immune checkpoints predict heart failure outcomes

Abstract Aims There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). Methods and results Transcriptomic an...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Elles M. Screever, Laura I.E. Yousif, Javid J. Moslehi, Joe‐Elie Salem, Adriaan A. Voors, Herman H.W. Silljé, Rudolf A. deBoer, Wouter C. Meijers
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Wiley 2023-08-01
Reeks:	ESC Heart Failure
Onderwerpen:	Immune checkpoints PD‐L1 PD‐L2 Galectin‐9 Heart failure
Online toegang:	https://doi.org/10.1002/ehf2.14304

Gelijkaardige items

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
door: Douglas B. Johnson, et al.
Gepubliceerd in: (2019-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
door: Federica Costa, et al.
Gepubliceerd in: (2018-09-01)

The role of immune checkpoints in cardiovascular disease
door: Laura I. Yousif, et al.
Gepubliceerd in: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
door: Vickram A S, et al.
Gepubliceerd in: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
door: Ruby Dhar, et al.
Gepubliceerd in: (2023-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
door: Kazuhiko Hashimoto, et al.
Gepubliceerd in: (2020-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
door: Jing Huang, et al.
Gepubliceerd in: (2017-05-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
door: Juwon Lee, et al.
Gepubliceerd in: (2021-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
door: Ruiting Li, et al.
Gepubliceerd in: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
door: Sai Mummareddy, et al.
Gepubliceerd in: (2021-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
door: Tianrui Yang, et al.
Gepubliceerd in: (2021-02-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
door: Jan Willem Kleinovink, et al.
Gepubliceerd in: (2017-04-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
door: Sebastian Marwitz, et al.
Gepubliceerd in: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
door: Yavar Shiravand, et al.
Gepubliceerd in: (2022-04-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
door: YU Lin, et al.
Gepubliceerd in: (2021-08-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
door: Ahmed M. Basudan
Gepubliceerd in: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
door: Gabriel Surdacki, et al.
Gepubliceerd in: (2019-03-01)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
door: Andreas von Knethen, et al.
Gepubliceerd in: (2021-10-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
door: Alberto Bongiovanni, et al.
Gepubliceerd in: (2021-05-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
door: Ya Xu, et al.
Gepubliceerd in: (2020-10-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
door: Edyta Zyla, et al.
Gepubliceerd in: (2021-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
door: Emily Hensler, et al.
Gepubliceerd in: (2022-07-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
door: Mihnea Dragomir, et al.
Gepubliceerd in: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
door: Maria Georganaki, et al.
Gepubliceerd in: (2018-12-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
door: William L. Redmond, et al.
Gepubliceerd in: (2023-02-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
door: Reid P. Bissonnette, et al.
Gepubliceerd in: (2021-08-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
door: Ji Won Han, et al.
Gepubliceerd in: (2021-09-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
door: Kübra KAHVECİ, et al.
Gepubliceerd in: (2019-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
door: Zachary S. Buchwald, et al.
Gepubliceerd in: (2018-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
door: Amjad Zafar, et al.
Gepubliceerd in: (2024-11-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
door: Jiaxin Zhou, et al.
Gepubliceerd in: (2022-07-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
door: Adel Naimi, et al.
Gepubliceerd in: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
door: Zhanjun Guo, et al.
Gepubliceerd in: (2022-03-01)

Profiling targetable immune checkpoints in osteosarcoma
door: Troy A McEachron, et al.
Gepubliceerd in: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
door: Deniz Can Guven, et al.
Gepubliceerd in: (2022-10-01)

Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
door: Kuti Baruch, et al.
Gepubliceerd in: (2020-05-01)

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
door: Leona Raskova Kafkova, et al.
Gepubliceerd in: (2024-02-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
door: Shuai Wang, et al.
Gepubliceerd in: (2018-08-01)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
door: Silvia Pesce, et al.
Gepubliceerd in: (2019-06-01)

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
door: Boris Klebansky, et al.
Gepubliceerd in: (2024-05-01)